Use of Intravenous Tranexamic Acid Improves Early Ambulation After Total Knee Arthroplasty and Anterior and Posterior Total Hip Arthroplasty


Authors:
Eugene S. Krauss, MD, FAAOS, FACS
MaryAnne Cronin, MS, PharmD, BCPS
Sanjeev J. Suratwala, MD, FAAOS, FACS
Paul Enker, MD, FRCS(C)
Lisa Rosen, ScM
Ayal Segal, MD

Author Affiliation | Disclosures

**Authors’ Disclosure Statement:** The authors report no actual or potential conflict of interest in relation to this article.

---

**Take-Home Points**

- IV-TXA significantly reduces intraoperative blood loss following TJA.
- Early mobilization correlates with reduced incidence of postoperative complications.
- IV-TXA minimizes postoperative anemia, facilitating improved early ambulation following TJA.
- IV-TXA significantly reduces the need for postoperative transfusions.
- IV-TXA is safe to use with no adverse events noted.

By the year 2020, use of primary total knee arthroplasty (TKA) in the United States will increase an estimated 110%, to 1.375 million procedures annually, and use of primary total hip arthroplasty (THA) will increase an estimated 75%, to more than 500,000 procedures. Minimizing perioperative blood loss and improving early postoperative ambulation both correlate with reduced postoperative morbidity, allowing patients to return to their daily lives expeditiously.

Tranexamic acid (TXA), a fibrinolytic inhibitor, competitively blocks lysine receptor binding sites of plasminogen, sustaining and stabilizing the fibrin architecture. TXA must be present to occupy binding sites before plasminogen binds to fibrin, validating the need for preoperative administration so the drug is available early in the fibrinolytic cascade. Intravenous (IV) TXA diffuses rapidly into joint fluid and the synovial membrane. Drug concentration and elimination half-life in joint fluid are equivalent to those in serum. Elimination of TXA occurs by glomerular filtration, with about 30% of a 10-mg/kg dose removed in 1 hour, 55% over the first 3 hours, and 90% within 24 hours of IV administration.

The efficacy of IV-TXA in minimizing total joint arthroplasty (TJA) perioperative blood loss has been proved in small studies and meta-analyses. TXA-induced blood conservation decreases or eliminates the need for postoperative transfusion, which can impede valuable, early ambulation. In addition, the positive clinical safety profile of TXA supports routine use of TXA in TJA.

The benefits of early ambulation after TJA are well established. Getting patients to walk on the day of surgery is a...
key part of effective and rapid postoperative rehabilitation. Early mobilization correlates with reduced incidence of venous thrombosis and postoperative complications. In contrast to bed rest, sitting and standing promotes oxygen saturation, which improves tissue healing and minimizes adverse pulmonary events. Oxygen saturation also preserves muscle strength and blood flow, reducing the risk of venous thromboembolism and ulcers. Muscle strength must be maintained so normal gait can be regained. Compared with rehabilitation initiated 48 to 72 hours after TKA, rehabilitation initiated within 24 hours reduced the number of sessions needed to achieve independence and normal gait; in addition, early mobilization improved patient reports of pain after surgery. An evaluation of Denmark registry data revealed that mobilization to walking and use of crutches or canes was achieved earlier when ambulation was initiated on day of surgery. Finally, mobilization on day of surgery and during the immediate postoperative period improved long-term quality of life after TJA.

We conducted a retrospective cohort study to determine if use of IV-TXA improves early ambulation and reduces blood loss after TKA and anterior and posterior THA. We hypothesized that IV-TXA use would reduce postoperative anemia and improve early ambulation and outcomes without producing adverse events during the immediate postoperative period. TXA reduces bleeding, and reduced incidence of hemarthrosis, wound swelling, and anemia could facilitate ambulation, reduce complications, and shorten recovery in patients who undergo TJA.

**Patients and Methods**

In February 2014, this retrospective cohort study received Institutional Review Board approval to compare the safety and efficacy of IV-TXA (vs no TXA) in patients who underwent TKA, anterior THA, and posterior THA.

In March 2012, multidisciplinary protocols were standardized to ensure a uniform hospital course for patients at our institution. All patients underwent preoperative testing and evaluation by a nurse practitioner and an anesthesiologist. In March 2013, IV-TXA became our standard of care. TXA use was contraindicated in patients with thromboembolic disease or with hypersensitivity to TXA. Patients without a contraindication were given two 10-mg/kg IV-TXA doses, each administered over 15 to 30 minutes; the first dose was administered before incision, and the second was infused at case close and/or at least 60 minutes after the first dose. Most TKA patients received regional (femoral) anesthesia and analgesia, and most THA patients received spinal or epidural anesthesia and analgesia. In a small percentage of cases, IV analgesia was patient-controlled, as determined by the pain service. There were no significant differences in anesthesia/analgesia modality between the 2 study groups—patients who received TXA and those who did not. Patients were then transitioned to oral opioids for pain management, unless otherwise contraindicated, and were ambulated 4 hours after end of surgery, unless medically unstable. Hematology and chemistry laboratory values were monitored daily during admission.

Patients underwent physical therapy (PT) after surgery and until hospital discharge. Physical therapists blinded to patients’ intraoperative use or no use of TXA measured ambulation. After initial evaluation on postoperative day 0 (POD-0), patients were ambulated twice daily. The daily ambulation distance used for the study was the larger of the 2 daily PT distances (occasionally, patients were unable to participate fully in both sessions). Patients received either enoxaparin or rivaroxaban for postoperative thromboprophylaxis (the anticoagulant used was based on surgeon preference). Enoxaparin was subcutaneously administered at 30 mg every 12 hours for TKA, 40 mg once daily for THA, 30 mg once daily for calculated creatinine clearance under 30 mL/min, or 40 mg every 12 hours for body mass index (BMI) 40 or above. With enoxaparin, therapy duration was 14 days. Oral rivaroxaban was administered at 10 mg once daily for 12 days for TKA and 35 days for THA unless contraindicated.

The primary outcome variables were ambulation measured on POD-1 and POD-2 and intraoperative blood loss. In addition, hemoglobin and hematocrit were measured on POD-0, POD-1, and POD-2. Ambulation was defined as
number of feet walked during postoperative hospitalization. To calculate intraoperative blood loss, the anesthesiologist subtracted any saline irrigation volume from the total volume in the suction canister. Also noted were postoperative transfusions and any diagnosis of postoperative venous thromboembolism—specifically, deep vein thrombosis (DVT) or pulmonary embolism (PE).

Demographic and clinical characteristics of the TXA and no-TXA groups were compared using either 2-sample t test (for continuous variables) or χ² test (for categorical variables).

The ambulation outcome was log-transformed to meet standard assumptions of Gaussian residuals and equality of variance. Means and 95% confidence intervals (CIs) were calculated on the log scale and were anti-logged so the results could be presented in their original units.

A linear mixed model was used to model intraoperative blood loss as a function of group (TXA, no TXA), procedure (TKA, anterior THA, posterior THA), and potential confounders (age, sex, BMI, operative time).

Linear mixed models for repeated measures were used to compare outcomes (hemoglobin, hematocrit) between groups (TXA, no TXA) and procedures (TKA, anterior THA, posterior THA) and to compare changes in outcomes over time. Group, procedure, and operative time interactions were explored. Potential confounders (age, sex, BMI, operative time) were included in the model as well.

A χ² test was used to compare the groups (TXA, no TXA) on postoperative blood transfusion (yes, no). Given the smaller number of events, a more complex model accounting for clustered data and potential confounders was not used. Need for transfusion was clinically assessed case by case. Symptomatic anemia (dyspnea on exertion, headaches, tachycardia) was used as the primary indication for transfusion once hemoglobin fell below 8 g/dL or hematocrit below 24%. Number of patients with a postoperative thrombus formation was minimal. Therefore, this outcome was described with summary statistics and was not formally analyzed.

Results

Of the 477 patients who underwent TJAs (275 TKAs, 98 anterior THAs, 104 posterior THAs; all unilateral), 111 did not receive TXA (June 2012-February 2013), and 366 received TXA (March 2013-January 2014). Other than for the addition of IV-TXA, the same standardized protocols instituted in March 2012 continued throughout the study period. The difference in sample size between the TXA and no-TXA groups was not statistically significant and did not influence the outcome measures.
There were no significant demographic or clinical differences between the TXA and no-TXA groups for all procedures (Table 1) or by procedure type (Table 2).

Table 1. Demographic and Clinical Characteristics of TXA and No-TXA Groups, All Procedures

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>TXA (n = 366)</th>
<th>No TXA (n = 111)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) age, y</td>
<td>66.4 (10.1)</td>
<td>66.8 (10.2)</td>
</tr>
<tr>
<td>Sex, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>61.9</td>
<td>56.8</td>
</tr>
<tr>
<td>Male</td>
<td>38.2</td>
<td>43.2</td>
</tr>
<tr>
<td>Mean (SD) body mass index, kg/m²</td>
<td>32.9 (9.1)</td>
<td>32.1 (8.5)</td>
</tr>
<tr>
<td>Operative time, min</td>
<td>100.2 (28.4)</td>
<td>101.5 (26.6)</td>
</tr>
<tr>
<td>Baseline hemoglobin, g/dL</td>
<td>13.0 (1.1)</td>
<td>13.9 (1.6)</td>
</tr>
<tr>
<td>Baseline hematoct, %</td>
<td>41.6 (4.8)</td>
<td>41.5 (4.3)</td>
</tr>
<tr>
<td>Incidence, %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>64.2</td>
<td>62.1</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>35.1</td>
<td>36.7</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>4.0</td>
<td>5.4</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>16.4</td>
<td>14.4</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>3.3</td>
<td>1.8</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>4.4</td>
<td>5.4</td>
</tr>
</tbody>
</table>

Table 2. The majority of patients were female (60.59%). Patients ranged in age from 32 to 93 years.

### Ambulation

There was a significant ($P = .0066$) 3-way interaction of TXA, procedure, and operative time after adjusting for age ($P < .0001$), sex ($P < .0001$), BMI ($P < .0001$), and operative time ($P = .8308$). Regarding TKA, mean ambulation was higher for the TXA group than for the no-TXA group at POD-1 (8.36 vs 3.40 feet; $P < .0001$) and POD-2 (25.81 vs 18.75 feet; $P = .0054$). The same was true for anterior THA at POD-1 (10.86 vs 3.33 feet; $P < .0001$) and POD-2 (27.24 vs 13.19 feet; $P < .0001$) and posterior THA at POD-1 (10.64 vs 3.37 feet; $P < .0001$) and POD-2 (24.68 vs 12.93 feet; $P = .0002$). See Table 3.
Intraoperative Blood Loss

There was a significant 3-way interaction of TXA, procedure ($P < .0053$), and operative time ($P < .0001$) after adjusting for age ($P < .6136$), sex ($P = .1147$), and BMI ($P = .6180$). Regarding TKA, mean intraoperative blood loss was significantly lower for the TXA group than for the no-TXA group (241.58 vs 287.81 mL; $P = .0004$). The same was true for anterior THA (352.91 vs 533.79 mL; $P < .0001$). Regarding posterior THA, there was no significant difference between the TXA and no-TXA groups (326.00 vs 350.16 mL; $P = .3246$). See Table 4.

Hemoglobin

There was a significant ($P = .0008$) 3-way interaction of TXA, procedure, and operative time after adjusting for age ($P = .0174$), sex ($P < .0001$), BMI ($P = .0007$), and operative time ($P = .0002$). Regarding TKA, postoperative hemoglobin levels were higher for the TXA group than for the no-TXA group at POD-0 (12.10 vs 11.68 g/dL; $P = .0135$), POD-1 (11.62 vs 10.67 g/dL; $P < .0001$), and POD-2 (11.02 vs 10.11 g/dL; $P < .0001$). The same was true for anterior THA at POD-1 (11.03 vs 10.19 g/dL; $P = .0034$) and POD-2 (10.57 vs 9.64 g/dL; $P = .0009$) and posterior THA at POD-2 (11.04 vs 10.16 g/dL; $P = .0003$). See Table 5.
Table 5.

**Hematocrit**

There was a significant \( P < .0006 \) 3-way interaction of TXA, procedure, and operative time after adjusting for age \( (P = .1597) \), sex \( (P < .0001) \), BMI \( (P < .0001) \), and operative time \( (P = .0003) \). Regarding TKA, postoperative hematocrit levels were higher for the TXA group than for the no-TXA group at POD-0 \( (36.52\% \text{ vs } 34.65\%; P < .0001) \), POD-1 \( (34.62\% \text{ vs } 31.83\%; P < .0001) \), and POD-2 \( (33.01\% \text{ vs } 30.20\%; P < .0001) \). The same was true for anterior THA at POD-1 \( (32.82\% \text{ vs } 30.59\%; P = .0037) \) and POD-2 \( (31.58\% \text{ vs } 28.61\%; P = .0004) \) and posterior THA at POD-2 \( (32.93\% \text{ vs } 30.17\%; P < .0001) \). See Table 6.

Table 6.

**Postoperative Transfusions**

Of the 477 patients, 25 \( (5.24\%) \) required a postoperative transfusion. Postoperative transfusions were less likely \( (P < .0001) \) required in the TXA group \( (1.64\%, 6/366) \) than in the no-TXA group \( (17.12\%, 19/111) \). Given the smaller number of events, a more complex model accounting for clustered data and potential confounders was not used, and the different procedures were not evaluated separately.
Deep Vein Thrombosis and Pulmonary Embolism

Of the 477 patients, 2 developed a DVT, and 5 developed a PE. Both DVTs occurred in the TXA group (2/366, 0.55%; 95% CI, 0.07%-1.96%). Of the 5 PEs, 4 occurred in the TXA group (4/366, 1.09%; 95% CI, 0.30%-2.77%), and 1 occurred in the no-TXA group (1/111, 0.90%; 95% CI, 0.02%-4.92%). Given the exceedingly small number of events, no statistical significance was noted between groups.

Discussion

Orthopedic surgeons carefully balance patient expectations, societal needs, and regulatory mandates while providing excellent care and working under payers’ financial restrictions. The Centers for Medicare & Medicaid Services announced that, starting in 2016, TJAs will be reimbursed in total as a single bundled payment, adding to the need to provide optimal care in a fiscally responsible manner. Standardized protocols implementing multimodal therapies are pivotal in achieving favorable postoperative outcomes.

Our study results showed that IV-TXA use minimized hemoglobin and hematocrit reductions after TKA, anterior THA, and posterior THA. Postoperative anemia correlates with decreased ambulation ability and performance during the early postoperative period. In general, higher postoperative hemoglobin and hematocrit levels result in improved motor performance and shorter recovery. In addition, early ambulation is a validated predictor of favorable TJA outcomes. In our study, for TKA, anterior THA, and posterior THA, ambulation on POD-1 and POD-2 was significantly better for patients who received TXA than for patients who did not.

Transfusion rates were markedly lower for our TXA group than for our no-TXA group (1.64% vs 17.12%), confirming the findings of numerous other studies on outcomes of TJA with TXA. Transfusions impede physical therapy and affect hospitalization costs.

Although potential thrombosis-related adverse events remain an endpoint in studies involving TXA, we found a comparably low incidence of postoperative venous thrombosis in our TXA and no-TXA groups (1.09% and 0.90%, respectively). In addition, no patient in either group developed a postoperative arterial thrombosis.

This is the largest single-center study of TXA use in TKA, anterior THA, and posterior THA. The effect of TXA use on postoperative ambulation was not previously found with TJA.

This study had its limitations. First, it was not prospective, randomized, or double-blinded. However, the physical therapists who mobilized patients and recorded ambulation data were blinded to the study and its hypothesis and followed a standardized protocol for all patients. In addition, intraoperative blood loss was recorded by an anesthesiologist using a standardized protocol, and patients received TXA per orthopedic protocol and surgeon preference, without selection bias. Another limitation was that ambulation data were captured only for POD-1 and POD-2 (most patients were discharged by POD-3). However, a goal of the study was to capture immediate postoperative data in order to determine the efficacy of intraoperative TXA. Subsequent studies can determine if this early benefit leads to long-term clinical outcome improvements.

In reducing blood loss and transfusion rates, intra-articular TXA is as efficacious as IV-TXA. We anticipate that the improved clinical outcomes found with IV-TXA in our study will be similar with intra-articular TXA, but more study is needed to confirm this hypothesis.
Conclusion

This retrospective cohort study found that use of IV-TXA in TJA improved early ambulation and clinical outcomes (reduced anemia, fewer transfusions) in the initial postoperative period, without producing adverse events.

Key Info

Figures/Tables

References

References


undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014;349:g4829.


24. Martin JG, Cassatt KB, Kincaid-Cinnamon KA, Westendorf DS, Garton AS, Lemke JH. Topical


Multimedia

Product Guide

- Med4 Elite®
- GRPro 2.1®
- Shoulder Wrap
- Knee Wrap

Citation

Eugene S. Krauss, MD, FAAOS, FACS MaryAnne Cronin, MS, PharmD, BCPS Sanjeev J. Suratwala, MD, FAAOS, FACS Paul Enker, MD, FRCS(C) Lisa Rosen, ScM Ayal Segal, MD. Use of Intravenous Tranexamic Acid Improves Early Ambulation After Total Knee Arthroplasty and Anterior and Posterior Total Hip Arthroplasty. Am J Orthop. 2017 September;46(5):E314-E319

Eugene S. Krauss, MD, FAAOS, FACS